View Schedule

Monday, Nov. 9, 2020

Pre-Conference Program

Tuesday, Nov. 10, 2020 

Pre-Conference Program

TBA

Primer on Tumor Immunology and Cancer Immunotherapy™

TBA

TBA

TBA

Engineering Immune Cells for Cancer Therapy 

TBA Introduction

Session I: Advances in Adoptive T cell Therapy for Cancer: TILs and TCRs

TBA

Neoantigen-expanded T cells/TCRs

TBA

TILs
John Haanen, MD, PhD – Netherlands Cancer Institute

TBA

Endogenous T cells
Cassian Yee, MD – The University of Texas MD Anderson Cancer Center

TBA

Session I Panel Discussion

TBA

Break

Session II: Novel Approaches to Enhance CAR T cell Therapy

TBA

Next-generation CARs for blood cancers

TBA

CAR for solid tumors
Saul Priceman, PhD – City of Hope

TBA

Resistance and next-generation approaches 
Marco Ruella, MD – University of Pennsylvania

TBA

Session II Panel Discussion 

TBA

Lunch

Session III: CAR-Based Strategies Beyond T Lymphocytes
TBA

NK cells
Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center

TBA

Macrophages
Michael Klichinsky, PharmD, PhD – Carisma Therapeutics

TBA

B cells
Justin Taylor, PhD – Fred Hutchinson Cancer Research Center

TBA

Session III Panel Discussion

TBA

Break

Session IV: Integration of Novel Technologies for CAR Therapy and their Translation to the Clinic
TBA

Novel concepts in manufacturing
Isabelle
Rivière, PhD – Memorial Sloan Kettering Cancer Center

TBA

Off-the-shelf, including allogeneic and iPSCs
Barbra Sasu, PhD – Allogene Therapeutics

TBA

Genetic engineering and novel approaches
Carl June, MD – University of Pennsylvania

TBA

Session IV Panel Discussion

 

Grant Writing Workshop

Wednesday, Nov. 11, 2020

Annual Meeting

TBA*
*Dates, times and program schedule subject to change. 

Presidential Welcome

TBA

Mario Sznol, MD – Yale School of Medicine

Session 100: Update Session

TBA

TBA

Session 101: Richard V. Smalley, MD Memorial Award and Lectureship

TBA

The PD-L1/PD-1 Pathway: Discovery and New Insights
Gordon Freeman, PhD – Dana-Farber Cancer Institute

TBA

Why Were We Interested in Immunity Within the Tumor Microenvironment in the 1990s?
Lieping Chen, MD, PhD – Yale School of Medicine

TBA

Discovery of New IO Targets and Mechanisms Leveraging CRISPR
Arlene Sharpe, MD, PhD – Harvard Medical School

Session 102: Combinatorial Therapies
Co-Chairs:
Charlotte E. Ariyan, MD, PhD – Memorial Sloan Kettering Cancer Center
Silvia Formenti, MD Weill Cornell Medicine

TBA

TBA

Session 103: Late-Breaking Abstract Session

TBA

Abstract

TBA

Abstract

Lunch & Poster Viewing

TBA



Session 104: NCI Session on Integrating Radiation and Immunotherapy

TBA

Introduction
Andrew Sikora, MD, PhD University of Texas MD Anderson Cancer Center

TBA

The Immuno-Radiobiology of Radiation Therapy
Ralph Weichselbaum, MD – University of Chicago

TBA

Preclinical and Translational Studies of Radiation and Immunotherapy

TBA

Design of Clinical Trials Integrating Radiation and Immunotherapy
Jonathan D. Schoenfeld, MD, MPhil, MPH Harvard University

TBA

NCI SBIR Opportunities

TBA

Best Practices and Future Perspectives for Integrating Radiation and Immunotherapy Panel Discussion
Sue L. Currie, PhD Nektar Therapeutics
Sandra Demaria, MD Weill Cornell Medicine
Jonathan D. Schoenfeld, MD, MPhil, MPH Harvard University
Ralph Weichselbaum, MD University of Chicago
Kristina H. Young, MD, PhD Earle A. Chiles Research Institute

TBA

Closing Remarks

Meet-the-Expert Lunch

TBA



Session 105: Toxicities
Co-Chairs:
Caroline Robert, MD, PhD – Institut Gustave Roussy
Cameron J. Turtle, MBBS, PhD, FRACP – Fred Hutchinson Cancer Research Center

TBA

Toxicities from ICIs: What Have We Learnt?
Caroline Robert, MD, PhD – Institut Gustave Roussy

TBA

Factors Associated with Toxicities of CD19 CAR-T cell Immunotherapy
Cameron J. Turtle, MBBS, PhD, FRACP – Fred Hutchinson Cancer Research Center

TBA

CAR-T Studies

TBA

Abstract

TBA

Abstract

TBA

Break

Concurrent Session 106: Developing Cellular Therapies for Solid Cancers
Co-Chairs:
Stephanie L. Goff, MD, FACS – National Cancer Institute
Avery Posey, PhD – University of Pennsylvania School of Medicine

TBA

TILS
Michal Besser, PhD – The Sheba Medical Center at Tel Hashomer

TBA

TCR Cells
James C. Yang, MD – National Cancer Institute

TBA

CAR for Solid Tumors
Avery Posey, PhD – University of Pennsylvania School of Medicine

TBA

NKT Cells
Andras A. Heczey, MD – Baylor College of Medicine

TBA

Abstract

Concurrent Session 107: Neoadjuvant Immunotherapies
Co-Chairs:
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
Janis M. Taube, MD, MSc – Johns Hopkins School of Medicine

TBA

Pan-Tumor Pathologic Response Assessment
Janis M. Taube, MD, MSc – Johns Hopkins School of Medicine

TBA

Neoadjuvant Breast Cancer
Elizabeth A. Mittendorf, MD, PhD – Dana-Farber Cancer Institute Brigham & Woman's Cancer Institute

TBA

Bladder Cancer
Jianjun Gao, MD, PhD – The University of Texas MD Anderson Cancer Center

TBA

Abstract

TBA

Abstract

Concurrent Session 108: Diet and Microbiome
Co-Chairs:
Jeremiah Faith, PhD – Icahn Institute for Data Science and Genomic Technology at Mt. Sinai
Laurence Zitvogel, MD, PhD – Institut Gustave Roussy

TBA

Introduction into Microbiome & Diet
Jeremiah Faith, PhD – Icahn Institute for Data Science and Genomic Technology at Mt. Sinai

TBA

Basic Research and Concepts: Metabolism, Microbiome, and Cancer (Cell Metabolism, Hunger Protein and Anticancer Effects)

TBA

Prebiotics and ICI (Camu-camu and Antitumor Efficacy)
Bertrand Routy, MD, PhD – CHUM Research Centre

TBA

Interventional Nutrition in Melanoma: Melanoma, Pre and Probiotics
Jennifer L. McQuade, MD – The University of Texas MD Anderson Cancer Center

TBA

Abstract

Concurrent Session 109: Innate Immunity: The Next Generation of Targets for Anti-Cancer Immunotherapy
Co-Chairs:
Jennifer L. Guerriero, PhD – Dana-Farber Cancer Institute
Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center

TBA

Tumor-Associated Macrophages
Jennifer L. Guerriero, PhD – Dana-Farber Cancer Institute

TBA

Gamma-delta T cells
Adrian Hayday, FRS, F MedSci – Gamma Delta Therapeutics

TBA

NK Cells
Andreas Lundqvist, PhD – Karolinska Institutet

TBA

Abstract

TBA

Abstract

Thursday, Nov. 12, 2020

Annual Meeting

TBA*
*Dates, times and program schedule subject to change. 

Organizer Welcome

TBA

TBA

Session 200: Update Session

TBA

TBA

Session 201: Keynote Address
Chair:
Mario Sznol, MD – Yale School of Medicine

TBA

Introduction
Mario Sznol, MD – Yale School of Medicine

TBA

Turning Immunologically Quiescent Tumors into Immune Responsive Cancers
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University

TBA

Q&A
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University

Session 202: Exploring the Tumor Microenvironment
Co-Chairs:
Vincenzo Bronte, MD – University of Verona
Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai

TBA

Introduction

TBA

Inflammatory Microenvironment

TBA

GBM
Shannon J. Turley, PhD – Genentech

TBA

Exploring the Tumor Microenvironment with CRISPR
Brian D. Brown, PhD – Icahn School of Medicine at Mount Sinai

TBA

Abstract

TBA

Abstract

Session 203: Late-Breaking Abstract Session

TBA

Abstract

TBA

Abstract

Session 204: Update Session

TBA

TBA

Lunch & Poster Viewing

TBA



Concurrent Rapid Oral Abstract Presentation Session 205: Basic Research

TBA

Abstract

TBA

Abstract

TBA

Abstract

TBA

Q&A

TBA

Abstract

TBA

Abstract

TBA

Abstract

TBA

Q&A

Concurrent Rapid Oral Abstract Presentation Session 206: Clinical

TBA

Abstract

TBA

Abstract

TBA

Abstract

TBA

Q&A

TBA

Abstract

TBA

Abstract

TBA

Abstract

TBA

Q&A

Session 207: Presidential Session
Chair:
Mario Sznol, MD – Yale School of Medicine

TBA

Introduction
Mario Sznol, MD – Yale School of Medicine

TBA

Abstract

TBA

Abstract

TBA

Expert Discussant

TBA

Abstract

TBA

Abstract

TBA

Expert Discussant

TBA

Break

Concurrent Session 208: Vaccines and Immunoprevention
Co-Chairs:
Shizuko Sei, MD – National Cancer Institute
Catherine J. Wu, MD – Dana-Farber Cancer Institute

TBA

Tumor Immune Surveillance

TBA

Antigen selection for Cancer Vaccines
Catherine J. Wu, MD – Dana-Farber Cancer Institute

TBA

Cancer Vaccines for Lynch Syndrome Carrier
Eduardo Vilar-Sanchez, MD, PhD  The University of Texas MD Anderson Cancer Center

TBA

Abstract

Concurrent Session 209: Gene Editing
Co-Chairs:
Helen E. Heslop, MD – Baylor College of Medicine
Carl H. June, MD – University of Pennsylvania

TBA

Panelist

 

Panelist

 

Panelist

 

Panelist

 

Panelist

 

Panelist

Concurrent Session 210: Bispecific Antibodies and Cancer Immunotherapy
Co-Chairs:
Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.
Mario Sznol, MD – Yale School of Medicine

TBA

TBA

Concurrent Session 211: Immunometabolism and ICI Resistance
Co-Chairs:
Susan M. Kaech, PhD – Salk Institute
Maxim N. Artyomov, PhD – Washington University School of Medicine in St. Louis

TBA

Metabolic Regulation of Anti-Tumor NK cells

TBA

Metabolic Processes that Affect Anti-Tumor Immune Responses
Santosh Vardhana, MD, PhD – Memorial Sloan Kettering Cancer Center

TBA

Energizing Anti-Tumor T cell Responses via Glutamine Metabolism
Jonathan D. Powell, MD, PhD – Johns Hopkins Medicine

TBA

Abstract

TBA

Break

Concurrent Session 212: Novel immunotherapies in myeloid malignancies
Co-Chairs:
Naval Daver, MD – The University of Texas MD Anderson Cancer Center
Marcela V. Maus, MD, PhD – Massachusetts General Hosptial

TBA

CD47 Macrophage Checkpoint-Based Immunotherapy (Lymphomas, MDS, AML)
David Sallman, MD  Moffitt Cancer Center

TBA

Bispecific Antibodies
Marion Subklewe, MD – University of Munich

TBA

CAR T for AML
Elizabeth Budde, MD, PhD – City of Hope

TBA

Abstract

TBA

Abstract

Concurrent Session 213: Reverse Translation for Clinical Trials
Co-Chairs:
Matthew Galsky, MD – Tisch Cancer Institute at Mount Sinai Medical Center
Padmanee Sharma, MD, PhD
 – The University of Texas MD Anderson Cancer Center

TBA

TBA
Sangeeta Goswami, MD, PhD – MD Anderson Cancer Center

TBA

Clinical Trial Design Considerations to Facility Reserve Translation
Thomas Marron, MD, PhD – Icahn School of Medicine at Mount Sinai

TBA

Identifying Novel Therapeutics Targets to Overcome Immune Checkpoint Blockade Resistance Through Reverse Translation
Sanjeev Mariathasan, PhD – Genentech

TBA

Abstract

TBA

Abstract

Concurrent Session 214: Engineering Immunity: Biomolecular and Genetic Approaches to Generating Novel Therapeutic Function
Co-Chairs:
Yvonne Chen, PhD – University of California, Los Angeles
Kole T. Roybal, PhD – University of California, San Francisco

TBA

Biomaterials – Basic Biology
Jennifer H. Elisseeeff, PhD – Johns Hopkins School of Medicine

TBA

Biomaterials – Immunotherapy
Darrell J. Irvine, PhD – MIT

TBA

Gene Editing

TBA

Abstract

Concurrent Session 215: B Cells
Co-Chairs:
Tullia Bruno, PhD – UPMC Hillman Cancer Center
Wolf Fridman, MD, PhD – Cordeliers Research Centre

TBA

B cells and TLS in Sarcoma Patients (Cold Tumor)
Wolf H. Fridman, MD, PhD – Cordeliers Research Centre

TBA

B cells and TLS in Melanoma Patients (Hot Tumor)

TBA

Virally Driven Cancer (HPV) and B cells and TLS or the Role of B cells in Lung Cancer Development and Progression
Tullia C. Bruno, PhD – UPMC Hillman Cancer Center

TBA

Abstract

TBA

Expert Discussant
Brad Nelson, PhD – Deely Research Centre at BC Cancer Agency

TBA

Q&A

Friday, Nov. 13, 2020

Annual Meeting

TBA*
*Dates, times and program schedule subject to change. 

Organizer Welcome

TBA

TBA

Session 300: Update Session

TBA

SITC Business Meeting

Session 301: 35th Anniversary Keynote Address
Chair:
Mario Sznol, MD – Yale School of Medicine

TBA

Introduction
Mario Sznol, MD – Yale School of Medicine

TBA

T cell Therapy of Cancer
Helen E. Heslop, MD – Baylor College of Medicine

TBA

Q&A
Helen E. Heslop, MD – Baylor College of Medicine

Session 302: Biomarkers and Big Data
Co-Chairs:
Michael Angelo, MD, PhD – Stanford University
Nir Hacohen, PhD – Broad Institute

TBA

Introduction
Nir Hacohen, PhD – Broad Institute

TBA

Spatial Analysis of Immune Responses in Tumors
Leeat Keren, PhD – Stanford University

TBA

Blood-Based Predictors of Tumor Immunity
Jane Grogan, PhD – Genentech

TBA

T cell States and Repertoire
Yardena Samuels, PhD – Weizmann Institute of Science

Session 303: Late-Breaking Abstract Session

TBA

Abstract

TBA

Abstract

Lunch

TBA



Concurrent Rapid Oral Abstract Presentation Session 304: Basic Research

TBA

Abstract

TBA

Abstract

TBA

Abstract

TBA

Q&A

TBA

Abstract

TBA

Abstract

TBA

Abstract

TBA

Q&A

Concurrent Rapid Oral Abstract Presentation Session 305: Clinical

TBA

Abstract

TBA

Abstract

TBA

Abstract

TBA

Q&A

TBA

Abstract

TBA

Abstract

TBA

Abstract

TBA

Q&A

Session 306: Hot Topic Symposium: COVID and Cancer

TBA

TBA

TBA

Break

Awards Ceremony
Chair:

Mario Sznol, MD – Yale School of Medicine

TBA

 

Session 307: 35th Anniversary Session: Mechanistic Understandings and Misunderstandings

Co-Chairs:
James P. Allison, PhD – The University of Texas MD Anderson Cancer Center
John Wherry, PhD – University of Pennsylvania

TBA

TBA

Saturday, Nov. 14, 2020

Annual Meeting

TBA*
*Dates, times and program schedule subject to change. 

Next Generation Immunotherapy Combinations: Navigating FDA, Clinical Trial Design, Diagnostics and Novel Biomarkers
Co-Chairs:
Emily Hopewell, PhD – Indiana University
Jason Luke, MD – UPMC Hillman Cancer Center

TBA

TBA

Schedule At-a-Glance

Monday, Nov. 9
Pre-Conference Programs
(Additional Fees Required)

Immunotherapy Resistance and Failure

Workshop on Engineering Immune Cells for Cancer Therapy

Tuesday, Nov. 10
Pre-Conference Programs
(Additional Fees Required)
Primer on Tumor Immunology and Cancer Immunotherapy™
Grant Writing Workshop
Wednesday, Nov. 11
Annual Meeting

35th Anniversary Annual Meeting

Thursday, Nov. 12
Annual Meeting

35th Anniversary Annual Meeting

Friday, Nov. 13
Annual Meeting


35th Anniversary Annual Meeting

Saturday, Nov. 14
Annual Meeting

35th Anniversary Annual Meeting